Tags

Type your tag names separated by a space and hit enter

Memantine for treatment of moderate to severe Alzheimer's disease.

Abstract

Health Canada has issued a Notice of Compliance with conditions (NOC/c) for memantine in the treatment of moderate to severe Alzheimer's disease (AD). The evidence of relative benefit and harm from memantine in this population derives from two randomized controlled trials (RCT) of 24 to 28 weeks duration, in a total of 656 patients; and a post hoc subgroup analysis of 79 patients with severe AD from a third trial of 12 weeks. Memantine alone or in combination with donepezil demonstrates improvements in primary outcome scores of activities of daily living and cognition, but not of global performance. Memantine's rate of diffusion may be rapid, as it is the only drug available for severe AD and it has a potential for use in unapproved indications.

Authors

No affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

15762015

Citation

Perras, C. "Memantine for Treatment of Moderate to Severe Alzheimer's Disease." Issues in Emerging Health Technologies, 2005, pp. 1-4.
Perras C. Memantine for treatment of moderate to severe Alzheimer's disease. Issues Emerg Health Technol. 2005.
Perras, C. (2005). Memantine for treatment of moderate to severe Alzheimer's disease. Issues in Emerging Health Technologies, (64), pp. 1-4.
Perras C. Memantine for Treatment of Moderate to Severe Alzheimer's Disease. Issues Emerg Health Technol. 2005;(64)1-4. PubMed PMID: 15762015.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Memantine for treatment of moderate to severe Alzheimer's disease. A1 - Perras,C, PY - 2005/3/15/pubmed PY - 2005/3/25/medline PY - 2005/3/15/entrez SP - 1 EP - 4 JF - Issues in emerging health technologies JO - Issues Emerg Health Technol IS - 64 N2 - Health Canada has issued a Notice of Compliance with conditions (NOC/c) for memantine in the treatment of moderate to severe Alzheimer's disease (AD). The evidence of relative benefit and harm from memantine in this population derives from two randomized controlled trials (RCT) of 24 to 28 weeks duration, in a total of 656 patients; and a post hoc subgroup analysis of 79 patients with severe AD from a third trial of 12 weeks. Memantine alone or in combination with donepezil demonstrates improvements in primary outcome scores of activities of daily living and cognition, but not of global performance. Memantine's rate of diffusion may be rapid, as it is the only drug available for severe AD and it has a potential for use in unapproved indications. SN - 1488-6316 UR - https://www.unboundmedicine.com/medline/citation/15762015/Memantine_for_treatment_of_moderate_to_severe_Alzheimer's_disease_ L2 - https://medlineplus.gov/dementia.html DB - PRIME DP - Unbound Medicine ER -